SCNX.US Scienture Holdings, Inc.

Healthcare Health Care Technology USA Stocks
2.76 USD
Close of Nov 18, 2026
2.64 18.75
Market cap
USD 4.93M
P/E
-
P/B
0.09x
ROE
-13,654.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SCNX.US undervalued?

Graham number

The Graham number of Scienture Holdings, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Scienture Holdings, Inc. fundamental analysis

No fundamental analysis for Scienture Holdings, Inc. yet.

Scienture Holdings, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Scienture Holdings, Inc.

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-…

Full company profile